Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
Q Biomed Inc. (OTCQB: QBIO) a commercial-stage biotechnology development company announces a new publication supporting the potential superior safety and efficacy of its Uttroside-B chemotherapeutic to treat liver cancer vs the current first line FDA approved drug....
Ashvattha Therapeutics Announces Publication of Data in Science Translational Medicine from Phase 2a Clinical Trial for OP-101 in Severe COVID-19
Ashvattha Therapeutics (“Ashvattha”), a clinical stage company developing novel hydroxyl dendrimer therapeutics, today announced the publication of the results from a Phase 2a clinical study demonstrating a significant reduction in inflammatory and neuroinflammatory...
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the first patient in China has been treated with TJ-CD4B (also known as ABL111), a novel...
Takeda Becomes Founding Sponsor of LabCentral to Help Life Sciences Startups Accelerate New Medical Treatments
LabCentral announced that Takeda, a global biopharmaceutical leader headquartered in Japan with a global U.S. hub located in Massachusetts, will become a LabCentral Founding Sponsor. Takeda will supply funding over a period of three years to support LabCentral's...
Roche Inks Potential $1B AAV Vector Deal with Avista for Eye Disease
Pittsburgh-based Avista Therapeutics has inked a partnership deal with Swiss pharma company Roche to develop AAV gene therapy vectors for eye diseases. The collaboration will use Avista’s single-cell adeno-associated virus (AAV) engineering platform, scAAVengr, to...
Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin
Adhera Therapeutics, Inc. (OTCQB: ATRX), a clinical stage biopharmaceutical company, announces that the Company has entered a Heads of Terms (also known as a Letter of Intent) agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin, a novel...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com